Abstract
AbstractBioactive small-molecule inhibitors represent a treasure chest for future drugs. In vitro high-throughput screening is a common approach to identify the small-molecule inhibitors that bind tightly to purified targets. Here, we investigate the inhibitor-target binding/unbinding kinetics in E. coli cells using a benzimidazole-derivative DNA inhibitor as a model system. We find that its unbinding rate is not constant but depends on cell growth rate. This dependence is mediated by the cellular activity, forming a feedback loop with the inhibitor’s activity. In accordance with this feedback, we find cell-to-cell heterogeneity in inhibitor-target interaction, leading to co-existence of two distinct subpopulations: actively growing cells that dissociate the inhibitors from the targets and non-growing cells that do not. We find similar heterogeneity for other clinical DNA inhibitors. Our studies reveal a mechanism that couples inhibitor-target kinetics to cell physiology and demonstrate the significant effect of this coupling on drug efficacy.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Research Corporation for Science Advancement
Publisher
Springer Science and Business Media LLC
Subject
General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference74 articles.
1. Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharm. 162, 1239–1249 (2011).
2. Decker, S. & Sausville, E. A. in Principles of Clinical Pharmacology 2nd edn (eds Arthur J. Atkinson et al.) 439–447 (Academic Press, 2007).
3. Croston, G. E. The utility of target-based discovery. Expert Opin. Drug Discov. 12, 427–429 (2017).
4. Alksne, L. E. & Dunman, P. M. Target-based antimicrobial drug discovery. Methods Mol. Biol. 431, 271–283 (2008).
5. Brown, D. Unfinished business: target-based drug discovery. Drug Discov. Today 12, 1007–1012 (2007).